Skin conditions (dermatitis, eczema, psoriasis) decisions — 2024

The Board denied service connection for the Veteran's skin disorder other than onychomycosis and remanded his claims for bilateral knee and eye conditions due to insufficient evidence.

The Veteran's residuals of pseudofolliculitis barbae are rated at 30 percent, but no higher, as the evidence shows that it affects three quarters of the exposed area of the anterior, lateral, and bilateral neck.

Service connection for anxiety and depression is denied.,Service connection for bilateral hearing loss, plantar fasciitis, and pseudofolliculitis barbae is denied.

The Board has determined that the Veteran's pre-existing eczema was aggravated by service, and therefore grants service connection for atopic dermatitis and eczema dermatitis.

The Veteran's initial claim for a higher rating for pseudofolliculitis barbae was granted with an effective date of November 15, 2019. The increased rating from 30% to 60% is subject to the laws and regulations governing the payment of monetary benefits.

The Veteran's claim for service connection for psoriasis (also claimed as signs or symptoms involving the skin) is remanded due to a lack of a VA examination. The Board finds that the evidence suggests a possible association with service, but an examination is needed to provide a definitive opinion.

The Veteran's tinea corporis, tinea pedis, and onychomycosis is not manifested by characteristic lesions involving at least 5 percent of the entire body affected or at least 5 percent of exposed areas affected. The Board denied a compensable rating as there was no evidence showing intermittent systemic therapy.

The Board has determined that there are errors in the decision and remands the case for a TERA specific examination to determine if the Veteran's airway hyperactivity, allergic rhinitis, and eczema are related to his service-connected toxic exposure in Jordan.

The Board has determined that the Veteran's acne disability may have begun during active service, and is remanding for a new VA medical opinion to determine if it is related to her in-service period of active duty.

The Board has denied service connection for COPD, diabetes mellitus, left shoulder joint pain, right shoulder joint pain, and hypertension/vasovagal syndrome. The remaining issues have been remanded due to the need for additional medical examinations.

The Board has granted service connection for pseudofolliculitis barbae, finding that the Veteran's skin symptoms began during active duty and have continued since separation. The decision is based on the Veteran's lay statements regarding his continuous skin symptoms both in and since service.

The Veteran's appeal for increased ratings on ten issues has been dismissed due to his withdrawal of the appeal.

The Veteran withdrew her appeals for all listed conditions, resulting in the dismissal of these claims.

The Veteran's anxiety and MDD are now rated at 50 percent, effective from the date of the decision. The other issues remain pending.

The Board remands the issue of entitlement to service connection for pseudofolliculitis barbae due to a pre-decisional duty-to-assist error, requiring a VA examination and medical opinion.

The Veteran's claim for a compensable rating for PFB with acne keloidalis nuchae, tinea pedis, and quiescent eczema is being remanded due to the AOJ failing to obtain an adequate medical examination during the pendency of the appeal.

The Board remands the issues for further development, including obtaining additional medical evidence and examinations to address the Veteran's claims.

The Board remands the claim for service connection for pseudofolliculitis barbae to obtain an adequate addendum medical opinion regarding its etiology, considering the Veteran's reports of continuous symptoms since service.

The Veteran was granted an initial disability rating of 60 percent for tinea pedis and onychomycosis, but a separately compensable rating for the left hand was denied.

The appeal for a higher initial evaluation than 10 percent for pseudofolliculitis barbae (PFB) has been withdrawn and is dismissed.